CICC Maintains Great Wall Pan Asia Holdings (02367.HK) with an "Outperform" Rating, Target Price Reduced to HK$40.

According to the Wisdom Financial APP, CICC released a research report stating that it maintains a "outperform" rating for Beike Biotechnology (02367.HK), based on the overall valuation pressure of the Hong Kong consumer sector, reducing the target price by 18% to HK$40. The bank maintains profit forecasts for Beike Biotechnology for 2026 and 2027. The current stock price corresponds to forecasted price-to-earnings ratios of 12 and 11 times for 2026 and 2027 respectively.